Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that ...
Versant Ventures has committed $30 million to improve gene delivery. By pumping the cash into Vector BioPharma, the VC is aiming to address the limitations of existing systems such as the cap on the ...
In a recent study posted to the bioRxiv* preprint server, researchers describe a mucosal vector vaccine for targeting dendritic cells. Study: A synthetic delivery vector for mucosal vaccination. Image ...
Investigators headed by a team at Brigham and Women’s Hospital have developed an adeno-associated virus (AAV) vector that studies show can far more efficiently cross the blood-brain barrier (BBB), in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results